<DOC>
	<DOCNO>NCT02354014</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetics ( explores body drug ) , anti-mycobacterial activity bedaquiline ( TMC207 ) child adolescent ( 0 month less [ &lt; ] 18 year age ) diagnose confirm probable pulmonary multidrug resistant tuberculosis ( MDR-TB ) , combination With Background Regimen ( BR ) MDR-TB Medications .</brief_summary>
	<brief_title>Pharmacokinetic Study Evaluate Anti-mycobacterial Activity TMC207 Combination With Background Regimen ( BR ) Multidrug Resistant Tuberculosis ( MDR-TB ) Medications Treatment Children/Adolescents Pulmonary MDR-TB</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , multicenter ( one hospital medical school team work medical research study ) Phase 2 study . The study consist screen phase , 24-week open-label treatment phase participant receive bedaquiline ( TMC207 ) combination BR MDR-TB medication , 96-week follow-up phase . Upon completion 24-week treatment bedaquiline , participant continue receive BR care investigator . The total study duration 120 week participant . There 4 age base cohort study . Cohort 1 : great equal ( &gt; = ) 12 less ( &lt; ) 18 year age ; Cohort 2 : &gt; =5 &lt; 12 year age ; Cohort 3 : &gt; =2 &lt; 5 year age ; Cohort 4 : 0 month &lt; 2 year age . Participants Cohorts 1 2 enrol concurrently follow sequential enrollment Cohorts 3 4 . An internal safety monitor group review safety pharmacokinetic data cohort determine subsequent cohort enrollment dose . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Multidrug-Resistant</mesh_term>
	<mesh_term>Bedaquiline</mesh_term>
	<mesh_term>Diarylquinolines</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<criteria>Participant must boy girl , age birth ( 0 month ) less ( &lt; ) 18 year screen . Infants must great equal ( &gt; = ) 37 week gestation baseline Participant must weigh &gt; 4 kilogram ( kg ) entry within 5th 95th percentile ( inclusive ) participant 's age , base World Health Organization ( WHO ) child growth standard ; Body Mass Index ( BMI ) age Heterosexually active girl may participate nonchildbearing potential , use effective birth control method willing continue practice birth control method throughout Multidrug Resistant Tuberculosis ( MDRTB ) treatment 6 month stop TMC207 treatment , nonheterosexually active willing practice sexual abstinence throughout MDRTB treatment Boys engage sexual activity could lead pregnancy female partner must use minimum male condom throughout MDRTB treatment 3 month stop TMC207 treatment Participants must start initial MDRTB regimen baseline start MDRTB regimen within 8 week baseline willing modify necessary acceptable MDRTB regimen use TMC207 Participant must willing permanently discontinue RMP least 7 day baseline visit Participant clinically significant active medical condition presence concomitant severe illness rapidly deteriorate health condition , include immune deficiency , opinion investigator would prevent appropriate participation study , would make implementation protocol interpretation study result difficult , otherwise make subject poor candidate clinical study Participant girl pregnant , breastfeeding , plan become pregnant enrolled study within 6 month stop TMC207 treatment Participant ( mother potential subject child age &lt; 6 month ) test positive Human Immunodeficiency Virus ( HIV ) screen within 1 month screen Participant know presume complicate severe extrapulmonary manifestation TB , include TB meningitis . Participants adenopathy adenitis allow enter study Participant significant cardiac arrhythmia require medication history risk factor Torsade de Pointes , example heart failure , hypokalemia , know personal family history Long QT Syndrome , untreated hypothyroidism</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Multidrug-Resistant Tuberculosis</keyword>
	<keyword>Bedaquiline</keyword>
	<keyword>TMC207</keyword>
</DOC>